Literature DB >> 17023834

Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.

Gang Xu1, Koji Kato, Tsutomu Toki, Yoshihiro Takahashi, Kiminori Terui, Etsuro Ito.   

Abstract

A Down syndrome male showed leukocytosis from birth and was diagnosed as transient myeloproliferative disorder (TMD). Eight months later, his condition had progressed to myelodysplastic syndrome after spontaneous resolution, and it then evolved to acute megakaryoblastic leukemia (AMKL) at the age of 20 months. Sequencing analysis showed that the predominant TMD and AMKL clones had different GATA1 mutations, although a minor TMD clone identical to the AMKL clone was present at birth. These observations suggest that a minor clone rather than the predominant clone at the time of TMD may give rise to AMKL later on.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023834     DOI: 10.1097/01.mph.0000212997.02554.f6

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

Review 2.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

3.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

4.  Transient abnormal myelopoiesis in a phenotypically normal newborn with polyclonal trisomy 21.

Authors:  Francesco Corazza; Annalisa Astolfi; Virginia Libri; Monica Franzoni; Salvatore Serravalle; Rosina Alessandroni; Fraia Melchionda; Andrea Pession
Journal:  Int J Hematol       Date:  2014-04-26       Impact factor: 2.319

Review 5.  Advances in molecular characterization of myeloid proliferations associated with Down syndrome.

Authors:  Jixia Li; Maggie L Kalev-Zylinska
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.